Business Context and Reporting Period
Company: ZIMMER BIOMET HOLDINGS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2026
Purpose: To recast financial information and disclosures in the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, due to changes in operating segment composition.
Key Financial Metrics
This filing does not contain specific revenue, profit, cash flow, margin, debt, or liquidity figures. It serves solely to announce the recasting of previously reported data. The filing lists the following registered securities:
- Common Stock, $0.01 par value (Symbol: ZBH)
- 2.425% Notes due 2026 (Symbol: ZBH 26)
- 1.164% Notes due 2027 (Symbol: ZBH 27)
- 3.518% Notes due 2032 (Symbol: ZBH 32)
Material Changes Versus Prior Period
The filing details a change in the Company's operating segment structure effective in the quarter ended March 31, 2026, driven by changes in senior leadership responsibilities reporting to the Chief Operating Decision Maker (CODM). The specific changes include:
- Segment Realignment: Results for the Foot and Ankle business in Europe, Middle East, Africa, and Asia Pacific are now included in the Americas operating segment.
- Expense Allocation: Certain product category expenses, including centralized research and development and global marketing, are now included in the Americas operating segment results.
Consequently, Part II, Item 7 (MD&A) and Part II, Item 8 (Financial Statements) of the 2025 Form 10-K have been recast in Exhibit 99.1 to reflect these new segment compositions.
Guidance, Outlook, and Risks
Management Commentary: The Company states that this 8-K is filed solely to recast historical financial information. It explicitly notes that Exhibit 99.1 does not update the MD&A for other information, developments, or events occurring after the 2025 Form 10-K filing date (February 20, 2026).
Forward-Looking Information: Investors are directed to subsequent filings, including Quarterly Reports on Form 10-Q and other Current Reports on Form 8-K, for updates on forward-looking statements and recent developments.
Risks and Contingencies: No new risks or contingencies are disclosed in this specific filing. The filing clarifies that the recast information is not an amendment or restatement of the 2025 Form 10-K but a reflection of segment composition changes.
Investor Verification Checklist
- Review Exhibit 99.1 attached to this filing for the specific recast financial tables and MD&A text.
- Compare the recast segment data in Exhibit 99.1 against the original February 20, 2026, Form 10-K to understand the impact of the Foot and Ankle and expense reallocations.
- Check subsequent Form 10-Q filings for the most current operational results and forward-looking guidance, as this 8-K does not update data post-February 2026.
- Verify the impact of the segment changes on the Americas operating segment's reported profitability and expense structure.